Bangavax gets ethical permission for human trials after 14 months
When the whole world is fighting a war against the repeated surge of new Covid-19 variants with era-defining vaccine technologies, Bangladesh is continuing a sloth paced system in developing a vaccine of its own.
Bangavax, the first candidate of the Covid-19 vaccine originated in Bangladesh has got ethical permission for human trial after 14 months of its first announcement.
Will this vaccine, when the country has been already conducting the Covid-19 vaccination programme in full swing with imported vaccines from all over the world, be of any use if it finally gets approval?
How many steps are left for it to get the final approval? Will this be able to tackle the newest variants such as Omicron?
In Straight from Star Newsroom, Debjani Shyama is joined by The Daily Star Senior Reporter Mohammad Al-Masum Molla to discuss the long-awaited ethical permission for the human trial of Bangavax.